Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

2010 SABCS: AZURE Trial Teleconference

December 10, 2010 6:32 am | by AACR | News | Comments

Robert E. Coleman, M.D., professor and honorary consultant medical oncologist at the Cancer Research Center, Academic Unit Medical of Clinical Oncology at Weston Park Hospital in Sheffield, England, presents the results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial at...

2010 SABCS:Patient Screening and Management Teleconference Recording

December 9, 2010 9:34 am | by AACR | News | Comments

AACR President-elect Judy Garber, M.D., M.P.H., director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute, moderates this press conference.

Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium

December 9, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

BRIDGEWATER, N.J., Dec. 9, 2010 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that the final survival analysis (10-year follow-up) of the BCIRG001 study that included a Taxotere® (docetaxel) Injection Concentrate chemotherapy treatment regimen in the adjuvant...

Advertisement

Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services

December 9, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

ALISO VIEJO, Calif., Dec. 9, 2010 /- Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter...

Caliper Life Sciences to Acquire Cambridge Research & Instrumentation

December 9, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

HOPKINTON and WOBURN, Mass., Dec. 9, 2010 /- Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research &...

Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test

December 9, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

ALISO VIEJO, Calif., Dec. 9, 2010 /- Clarient, Inc. (Nasdaq: CLRT ), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the...

Assured Pharmacy, Inc. Receives Gross Proceeds of $300,000 from Sale of Convertible Debentures and Warrants

December 8, 2010 3:39 pm | by Bio-Medicine.Org | News | Comments

FRISCO, Texas, Dec. 8, 2010 /- Assured Pharmacy, Inc. (Pink Sheets: APHY ) (the "Company"), a growing chain of specialty pharmacies that provides advanced prescription services to a diverse array of medical professionals and their patients, announced today that it sold in a private...

Amgen to Present at Deutsche Bank's 2010 BioFEST

December 8, 2010 3:39 pm | by Bio-Medicine.Org | News | Comments

THOUSAND OAKS, Calif., Dec. 8, 2010 /- Amgen (Nasdaq: AMGN ) will participate in Deutsche Bank's 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development and Arvind Sood,...

Advertisement

Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism

December 8, 2010 3:39 pm | by Bio-Medicine.Org | News | Comments

EMERYVILLE, Calif., Dec. 8, 2010 /- Bionovo, Inc. (Nasdaq: BNVI ) today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that...

Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis

December 8, 2010 3:38 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 8, 2010 /- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The...

Netsmart Technologies is First Behavioral Healthcare Software Provider to Attain Complete ARRA-Certified Electronic Health Record

December 8, 2010 3:38 pm | by Bio-Medicine.Org | News | Comments

GREAT RIVER, N.Y., Dec. 8, 2010 /- Netsmart Technologies, Inc., a leading provider of software and services for health and human services organizations, today announced that its Avatar™ 2011 electronic health record (EHR) software has achieved 100 percent ONC-ATCB ARRA ambulatory...

New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer(2)

December 8, 2010 3:37 pm | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 8, 2010 /- Androgen deprivation therapy has often been prescribed as a prostate cancer treatment for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions....

Streamline Health Solutions Reports Q3 Results

December 8, 2010 3:37 pm | by Bio-Medicine.Org | News | Comments

CINCINNATI, Dec. 8, 2010 /- Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced financial results for the third quarter of fiscal year 2010, ended October 31, 2010. Highlights for the quarter included: Revenue for the quarter increased 9% over prior year's comparable...

Advertisement

Uroplasty Announces Addition of Robert Kill to its Board of Directors

December 8, 2010 3:37 pm | by Bio-Medicine.Org | News | Comments

MINNEAPOLIS, Dec. 8, 2010 /- Uroplasty, Inc. (Nasdaq: UPI ), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors.  Mr. Kill's...

Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend

December 8, 2010 3:37 pm | by Bio-Medicine.Org | News | Comments

KALAMAZOO, Mich., Dec. 8, 2010 /- Stryker Corporation (NYSE: SYK ) announced today that its Board of Directors has increased its dividend by 20% by declaring a quarterly dividend of $0.18 per share payable on January 31, 2011, to shareholders of record at the close of business on December...

Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial

December 8, 2010 3:37 pm | by Bio-Medicine.Org | News | Comments

SUNRISE, Fla., Dec. 8, 2010 /- Bioheart, Inc. (OTC Bulletin Board: BHRT ) announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle...

Physicians exempt from Red Flags identity theft rule

December 8, 2010 3:36 pm | by Diagnostic Imaging | News | Comments

Doctors' groups, including the AMA and several specialty organizations, have lobbied aggressively to ensure that healthcare providers were not included under the law. The efforts, it turns out, were successful.

Society touts highlights of upcoming meeting

December 8, 2010 3:36 pm | by Diagnostic Imaging | News | Comments

The Society of Thoracic Radiology will host its 29th annual meeting March 6 to 9, 2011, at the Hyatt Regency Coconut Point resort in Bonita Springs, FL. The program committee, headed by Dr. Gerald F. Abbott, has designed a comprehensive course of value to all physicians with an interest...

ANTs Software Delivers the Perfect Prescription for Database and Application Migration to Large European Healthcare Provider(2)

December 8, 2010 3:35 pm | by RealWire | News | Comments

Migrate Highly Complex Applications Quickly with IBM® DB2® SQL Skin for applications compatible with Sybase ASESAN FRANCISCO—December 8, 2010-- One of Europe's largest and most advanced medical facilities will implement a sophisticated application and database migration...

Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile

December 8, 2010 8:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 8, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: Astellas Pharma Inc.: PharmaVitae Profile http://www.reportlinker.com/p0110534/Astellas-Pharma-Inc-PharmaVitae-Profile.html IntroductionThis analysis examines the...

Reportlinker Adds Asia-Pacific Orthopedic Devices Market Outlook to 2016

December 8, 2010 8:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 8, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: Asia-Pacific Orthopedic Devices Market Outlook to 2016 http://www.reportlinker.com/p0336530/Asia-Pacific-Orthopedic-Devices-Market-Outlook-to-2016.html Asia-Pacific...

Florida Metrology To Distribute OASIS Inspection Systems

December 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

MIDDLETOWN, Del., Dec. 8, 2010 /- George Products Company, Inc. has announced the addition of Florida Metrology as the newest distributor of its OASIS Inspection Systems. Florida Metrology, based in Jupiter, will distribute the product throughout southeast Florida. OASIS Inspection...

For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensiti...

December 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 8, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of...

Government Regulation of Drug Prices will Increase in Both Mature and Emerging Markets, Including Markets that Traditionally Play a Limited Role in Pharmaceutical Pricing

December 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 8, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pharmaceutical industry must prepare itself for an increasingly draconian drug pricing environment. While governments in...

Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer

December 8, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 8, 2010 /- Otonomy, Inc . announced today that David A. Weber, Ph.D. , has joined the company as president, CEO and member of the Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, co-founder of Otonomy and CEO since its inception, will continue...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading